CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary